Ghazanfar Mehboob | Material Science | Excellence in Design Award

Ghazanfar Mehboob | Material Science | Excellence in Design Award

Dr. Ghazanfar Mehboob at Guangzhou University | China

Dr. Ghazanfar Mehboob (Ph.D.) is a highly accomplished materials scientist specializing in thermal barrier coatings (TBCs), environmental barrier coatings (EBCs), plasma spraying, computational coating design, and advanced functional materials. He is currently a Postdoctoral Researcher at Guangzhou University, China, where he focuses on unraveling failure mechanisms in TBCs and developing optimized structural morphologies to extend coating lifespan through integrated experimental and numerical simulations. Dr. Mehboob completed his Ph.D. in Materials Science and Engineering at Xi’an Jiaotong University (2023), where he conducted pioneering research on strain-tolerant coating architectures, crack propagation behavior, multilayer thermal barrier systems, and substrate–coating interactions. His expertise spans Abaqus, FEM, VCCT, residual stress modeling, nanoparticle synthesis, thin films, multiferroics, solar cells, and advanced nanomaterials. He has produced a strong research output with 16 international publications, including 7 as first and corresponding author, and has accumulated 295 citations, reported across 282 citing documents, with an h-index of 8. His impactful contributions include advancements in WC-CoCr adhesion behavior, double-layer TBC design optimization, coating failure analysis, and temperature-dependent magnetic properties of spinel nanoparticles. Dr. Mehboob has been awarded the prestigious Guangzhou University Start-Up Research Fund (2025) for exploring new materials and long-lifespan coating strategies. Alongside his research achievements, he has served as a Lecturer and held leadership roles such as President of the Career Counseling Society, demonstrating strong academic, organizational, and mentoring capabilities. His work continues to advance high-performance coating technologies and functional materials for extreme-environment and energy-related engineering applications.

Profile:  Scopus | GoogleScholar
Featured Publications 

Mohamed Maher | Material Science | Impactful Research Award

Mohamed Maher | Material Science | Impactful Research Award

Dr. Mohamed Maher, University of Texas Southwestern Medical Center, United States.

Publication profile

Scopus

Education and Experience

Education 🎓
  • Ph.D. in Cancer Biology (Molecular Virology and Immunology) – National Cancer Institute, Cairo University, Egypt (2011–2017)
  • M.Sc. in Pharmaceutical Sciences (Microbiology and Immunology) – Assiut University, Egypt (2006–2010)
  • B.Sc. in Pharmaceutical Sciences – Assiut University, Egypt (1998–2003)
Experience 💼
  • Senior Research Assistant – MD Anderson Cancer Center, Houston, TX (2022–Present)
  • Postdoctoral Fellow – MD Anderson Cancer Center, Houston, TX (2019–2022)
  • Lecturer of Cancer Biology, Virology, and Immunology – South Egypt Cancer Institute, Assiut University, Egypt (2017–Present)
  • Assistant Lecturer – South Egypt Cancer Institute, Assiut University, Egypt (2015–2017)

Suitability For The Award

Dr. Mohamed Maher stands as a distinguished cancer researcher whose transformative contributions to molecular diagnostics and cancer genomics make him an ideal candidate for the prestigious Impactful Research Award. His innovative work in cancer genotyping, particularly in liquid biopsies, solid tumors, and hematological malignancies, underscores his dedication to advancing diagnostic precision and improving patient outcomes. Dr. Maher’s expertise, blending his background as a Clinical Pharmacist, Cancer Biologist, and Molecular Diagnostic innovator, highlights his remarkable ability to translate cutting-edge research into real-world clinical applications, creating a lasting impact in cancer research and diagnostics.

Professional Development 

Publications Top Notes

  • “A rapid turnaround time workflow for a cytological liquid biopsy assay using FNA supernatant specimens” (Maher, M.H., et al., 2025, Cancer Cytopathology) – 📅 2025 | 🔗 Open Access | ✨ 
  • “Dinutuximab synergistically enhances the cytotoxicity of natural killer cells to retinoblastoma through the perforin-granzyme B pathway” (Wang, H., et al., 2020, OncoTargets and Therapy) – 📅 2020 | 🔗 8 Citations